IZO

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a company commercializing true 3D, dedicated breast CT imaging technology for the earlier detection, diagnosis and treatment of breast cancers, is pleased to unveil its highly anticipated breast…...

Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a company commercializing true 3D, dedicated breast CT imaging technology for the earlier detection, diagnosis and treatment of breast cancers, is pleased to announce it has upgraded its…...

Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTC US: IZOZF) (FSE: 1R3) is pleased to announce the addition of Jeff Siewerdsen Ph.D. to the Company’s Scientific Advisory Board, comprised of industry experts and authorities in their respective fields.Dr. Siewerdsen…...

Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTC US: IZOZF) (FSE: 1R3) is pleased to provide an update on corporate and commercialization progress and its positioning for 2021. Izotropic achieved important milestones in 2020 and added experienced medical device…...

Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTC US: IZOZF) (FSE: 1R3) is pleased to highlight the appointment of Director and Principal Founder of Breast CT Technology, Dr. John M. Boone, as the Editor-In-Chief of the American Association of…...

Izotropic Corporation ("Izotropic" or the "Company") (CSE: IZO) (OTC US: IZOZF) (FSE: 1R3) announces it has received the finalized meeting minutes from the U.S. Food and Drug Administration (FDA) in connection with the Company's recent pre-submission meeting and the market…...

Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) is pleased to announce that it has completed a non-brokered private placement financing (the “Offering”) of 1,896,679 units of the Company (each, a “Unit”) at a price of $0.90 per Unit for…...

Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTC US: IZOZF) (FSE: 1R3) – Further to the Company’s News Release of October 20, 2020, the Company is pleased to announce that it has completed the second and final tranche of…...

Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTC US: IZOZF) (FSE: 1R3) is pleased to announce a non-brokered private placement financing (the “Offering”) of up to 6,000,000 units of the Company (each, a “Unit”) at a price of $0.55…...

Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTC US: IZOZF) (FSE: 1R3) is pleased to announce that the Company’s Executive and Scientific Advisory Teams will meet with ­­the U.S. Food and Drug Administration (FDA) on October 20, 2020....